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How advanced is breast cancer in Africa?
Breast cancer is a growing problem in low-resource 
settings. According to the GLOBOCAN database,1 
an estimated 94 378 new cases of breast cancer are 
diagnosed in sub-Saharan Africa annually. Incidence 
rates vary considerably between African countries—eg, 
38 new cases per 100 000 women per year in Kenya 
compared with 28 cases per 100 000 women per year 
in Uganda. An average increase in incidence rate of 
3·7 cases per 100 000 women per year was seen in the 
past 20 years in Uganda.2 The Concord study group 
has published survival data from individual patients 
from 279 population-based registries in 67 countries 
worldwide. Outcomes vary greatly between regions 
and improvements in survival were seen over time. 
The outcome was dependent on early diagnosis and 
access to therapy.3 Findings from hospital-based studies 
suggest that patients who actually receive therapy can 
have a good outcome; one such study from Ethiopia4 
reported a distant metastasis survival rate of 74% after 
2 years. 
Patients with breast cancer in Africa are often thought 
of as being young and presenting at a late stage of the 
disease. In The Lancet Global Health, Elima Jedy-Agba and 
colleagues5 present the ﬁ rst comprehensive systematic 
review and meta-analysis of breast cancer stage at 
diagnosis in sub-Saharan Africa. The authors included 
83 studies with 26 788 individuals. Most results 
were from consecutive or convenience case series at 
tertiary hospitals, an important source of information 
for health-care planning. Notably, the percentage of 
patients with late-stage (stage III/IV) cancer varied 
greatly between studies, ranging from 30% in South 
Africa to nearly 98% in one Nigerian study. The meta-
regression analysis revealed that urban populations 
and non-black South African populations had lower 
percentages of patients with late-stage breast cancer 
at diagnosis than black or mixed ethnic South African 
patients and those from rural or rural and urban 
backgrounds. Readers might have expected age, region, 
or type of health facility to aﬀ ect the percentage of 
women with late-stage breast cancer, but no diﬀ erences 
were seen. Information about late-stage breast cancer 
from a population-based cancer registry would be 
useful to account for the selection bias of hospitals. 
Population-based data showed that 74% of women in 
Côte d’Ivoire and 81% of women in Democratic Republic 
of the Congo had late-stage breast cancer in 2008–09.6 
Jedy-Agba and colleagues also report that the average 
age at diagnosis in sub-Saharan Africa (35–49 years) is 
lower than in high-income countries, which is due to 
the high proportion of young people in these countries. 
Others have shown that age-speciﬁ c incidence rates in 
young age groups in Africa do not diﬀ er when compared 
with European countries.7 These ﬁ ndings are evidence 
against the theory of a unique highly aggressive form 
of breast cancer in Africa. However, some diﬀ erences 
in tumour biology or genetics have been described in 
studies comparing African-American patients with 
white patients, which showed a slightly earlier onset of 
the disease and adverse outcome in African-American 
patients after adjusting for known adverse prognostic 
factors.8 These other known prognostic factors were 
not presented in most of the African papers and were 
therefore not reviewed by Jedy-Agba and colleagues. 
A debate about whether the advanced stages are due 
to a unique aggressive biology of the disease or a delay 
in presentation is ongoing. Jedy-Agba and colleagues 
found that the average time between self-reported 
onset of symptoms and time of diagnosis (analysed in 
35 studies) was 8–12 months, and was not signiﬁ cantly 
associated with late-stage disease. However, such delays 
between symptom onset and diagnosis and treatment 
need to be addressed to improve patient outcome. 
Awareness campaigns can improve health-care seeking 
behaviour and referral in symptomatic women to some 
extent, but the long-term eﬀ ect of early diagnosis on 
outcome has not been assessed in sub-Saharan Africa.
Trained volunteers and health-care workers have 
been shown to be able to do simpliﬁ ed screening to ﬁ nd 
advanced breast cancer at a village level.9,10 The need 
for patient advocates, such as survivors, and education 
of health-care workers to correctly help women with 
symptoms of breast cancer is evident. Their success will 
depend on the assurance of diagnosis and the availability 
of appropriate treatment. Pathology resources have to 
be sustainably developed across sub-Saharan Africa.11 
Palliative care for patients with late-stage breast cancer 
is much needed because the risk of metastasis in these 
patients is high. The ﬁ nancial burden for the average 
patient with breast cancer in sub-Saharan Africa should 
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also be considered in strategies to improve early 
diagnosis.
Jedy-Agba and colleagues found that women in 
Africa often present with late-stage breast cancer. 
The publications diﬀ er greatly in the percentage of 
patients with late-stage disease, but not according 
to African regions. The percentage of patients with 
late-stage disease was lower in solely non-black South 
Africans or patients from non-rural backgrounds than 
in black or mixed ethnic South Africans or those from 
rural or rural and urban backgrounds. The percentage 
of patients with late-stage disease reduced over time 
across all studies. These ﬁ ndings might encourage 
policy makers to design, implement, and monitor 
adequate cancer control plans. Political attention such 
as the Forum of African First Ladies Against Breast 
and Cervical Cancer initiative to “Stop Cervical, Breast 
and Prostate Cancer” will hopefully help to sustain the 
positive trend already seen.
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